CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 653.34 Million CNY | 194.12% |
| 2022 | -694.19 Million CNY | 82.99% |
| 2021 | -4.08 Billion CNY | 5.17% |
| 2020 | -4.3 Billion CNY | -11973.97% |
| 2019 | -35.65 Million CNY | -138.49% |
| 2018 | 92.61 Million CNY | 2.81% |
| 2017 | 90.08 Million CNY | 436.83% |
| 2016 | 16.78 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -465.37 Million CNY | -171.23% |
| 2024 Q2 | 474.94 Million CNY | 202.06% |
| 2023 Q2 | 54.08 Million CNY | 107.32% |
| 2023 FY | 653.34 Million CNY | 194.12% |
| 2023 Q4 | 653.34 Million CNY | 152.46% |
| 2023 Q3 | -1.24 Billion CNY | -2402.74% |
| 2023 Q1 | -738.48 Million CNY | -6.38% |
| 2022 Q2 | -1.62 Billion CNY | 41.12% |
| 2022 FY | -694.19 Million CNY | 82.99% |
| 2022 Q4 | -694.19 Million CNY | -26.26% |
| 2022 Q3 | -549.79 Million CNY | 66.12% |
| 2022 Q1 | -2.75 Billion CNY | 32.49% |
| 2021 Q4 | -4.08 Billion CNY | -2.9% |
| 2021 Q1 | -4.16 Billion CNY | 3.34% |
| 2021 Q2 | -3.59 Billion CNY | 13.68% |
| 2021 Q3 | -3.96 Billion CNY | -10.45% |
| 2021 FY | -4.08 Billion CNY | 5.17% |
| 2020 Q4 | -4.3 Billion CNY | -159.17% |
| 2020 FY | -4.3 Billion CNY | -11973.97% |
| 2020 Q2 | -391.68 Million CNY | 4.2% |
| 2020 Q3 | -1.66 Billion CNY | -324.03% |
| 2020 Q1 | -408.87 Million CNY | -1046.88% |
| 2019 Q4 | -35.65 Million CNY | 0.0% |
| 2019 FY | -35.65 Million CNY | -138.49% |
| 2019 Q2 | -281.74 Million CNY | -242.74% |
| 2019 Q1 | 197.38 Million CNY | 113.11% |
| 2018 FY | 92.61 Million CNY | 2.81% |
| 2018 Q1 | 420.88 Million CNY | 0.0% |
| 2018 Q3 | 92.61 Million CNY | 0.0% |
| 2018 Q4 | 92.61 Million CNY | 0.0% |
| 2017 FY | 90.08 Million CNY | 436.83% |
| 2016 FY | 16.78 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 352.546% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 67.845% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -10891.639% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | -116.672% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 3531.784% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -2011.099% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 398.018% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -155.049% |
| PuraPharm Corporation Limited | 377.54 Million HKD | -73.049% |
| SSY Group Limited | 1.71 Billion HKD | 61.871% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 8930.153% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | -93.616% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 98.718% |